SUO Annual Meeting | Conference

Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer

December 2nd 2017

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

Neoadjuvant Sonidegib Active in High-Risk Prostate Cancer

December 2nd 2017

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores

December 2nd 2017

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC

December 1st 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer

December 1st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC

December 1st 2017

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity

December 1st 2017

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

Dr. Sonpavde Discusses Current Clinical Trials in Penile Cancer

December 1st 2017

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses current clinical trials in penile cancer.

Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

December 1st 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

Plimack Recaps 2017 Immunotherapy Approvals in Bladder Cancer

December 1st 2017

It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.

Immunotherapy Combinations on the Rise for RCC

November 30th 2017

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer

November 30th 2017

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

November 30th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Immunotherapy Combo Regimens Next Step in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.